StockWire X
ASX:LTP

LTR Pharma Ltd (ASX:LTP) Share Price & Analysis

LTR Pharma is a clinical-stage biopharma company developing SPONTAN®, a fast-acting intranasal treatment that offers men with erectile dysfunction a rapid, on-demand alternative to traditional ED medications.

About (ASX:LTP)

LTR Pharma is a pioneering clinical-stage biopharmaceutical company focused on revolutionizing the treatment of Erectile Dysfunction (ED) through its innovative SPONTAN® intranasal technology. The company has developed a novel drug delivery platform that provides an on-demand solution for ED, with the ability to take effect in just 10 minutes, addressing a significant global health challenge that affects millions of men worldwide. The company's lead product, SPONTAN® (SDS-089), represents a breakthrough in ED treatment by offering a faster-acting, lower-dose alternative to traditional oral medications. By utilizing an intranasal delivery method, SPONTAN® promises reduced systematic exposure and fewer side effects compared to existing treatments. The technology aims to restore spontaneity in sexual health, with clinical data showing promising results, including a 100% patient satisfaction rate in post-prostatectomy case studies. With the global ED market projected to reach 322 million cases by 2025 and a market value of $7.10 billion by 2024, LTR Pharma is strategically positioned to disrupt the established PDE5 market. The company is advancing towards a fast-track US New Drug Application (NDA) filing within two years, demonstrating its commitment to providing an innovative, patient-friendly solution for a condition that significantly impacts both physical and psychological health.

Latest (ASX:LTP) Announcements

(ASX:LTP) Share Price Chart

Latest (ASX:LTP) News and Analysis

Educational Content Mentioning (ASX:LTP)

(ASX:LTP) Financials